6/29/23, 1:41 AM PORTEC-3 Pathway Feedback Search Clinical Topics Home Studies PORTEC 3 PORTEC 3 Disease Endometrial cancer Trial question Is adjuvant chemoradiotherapy superior to radiotherapy in women with high-risk endometrial cancer? Study design Multi-center Open label RCT Population 660 female patients Inclusion criteria: women with high-risk endometrial cancer Key exclusion criteria: uterine sarcoma; previous pelvic radiotherapy, hormonal therapy, or chemotherapy; bulky cervical involvement with radical hysterectomy; IBD; impaired renal or cardiac function Interventions N=330 chemoradiotherapy (radiotherapy plus chemotherapy consisting of two cycles of cisplatin 50 mg/m given during radiotherapy, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m ) N=330 radiotherapy (48.6 Gy in 1.8 Gy fractions given on 5 days per week) Primary outcome Overall survival at 5 years 81.8 % 81.8 76.7 61.3 % 40.9 % https://web.pathway.md/studies/recMdNYIB3HUpyuyA 1/2 6/29/23, 1:42 AM PORTEC-3 Pathway 20.4 % No significant difference 0.0 % Chemoradiotherapy Radiotherapy No significant difference in overall survival at 5 years (81.8% vs. 76.7%; HR 1.32, 95% CI 0.94 to 1.85) Secondary outcomes Significant increase in failure-free survival at 5 years (75.5% vs. 68.6%; HR 1.41, 95% CI 1.05 to 1.89) Significant decrease in pelvic recurrence (4.9% vs. 9.2%; HR 0.51, 95% CI 0.28 to 0.92) No significant difference in distant metastases (23.1% vs. 29.7%; HR 0.77, 95% CI 0.57 to 1.03) Safety outcomes No significant difference in hypertension. Significant differences in grade 3 or worse adverse events (60% vs. 12%), persistence of grade 2 neuropathy or worse at 3 years (8% vs. 1%). Conclusion In women with high-risk endometrial cancer, chemoradiotherapy was not superior to radiotherapy with respect to overall survival at 5 years. Reference Stephanie M de Boer, Melanie E Powell, Linda Mileshkin et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018 Mar;19(3):295- 309. Open reference URL https://web.pathway.md/studies/recMdNYIB3HUpyuyA 2/2